Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Cost of Free Pharmaceutical Services

Philip Seo, MD, MHS  |  Issue: October 2019  |  October 18, 2019


Philip Seo, MD, MHSPhilip Seo, MD, MHS, is an associate professor of medicine at the Johns Hopkins University School of Medicine, Baltimore. He is director of both the Johns Hopkins Vasculitis Center and the Johns Hopkins Rheumatology Fellowship Program.

References

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Friedman M. There’s No Such Thing as a Free Lunch. Chicago: Open Court Publishing Co., 1975.
  2. Ivins M. Notes from another country. The Nation. 1992 Sep 14.
  3. How GoodRx works. GoodRx. (n.d.).
  4. Farr C, Sherman A. GoodRx, a service for finding the best price on prescription drugs, is in sale talks for up to $3 billion. CNBC. 2018 Jun 20.
  5. Sheng E. This app has saved Americans $10 billion on prescriptions so far. CNBC. 2019 May 15.
  6. Hydroxychloroquine prices, coupons & patient assistance. GoodRx. (n.d.).
  7. What is GoodRx? How does it work? GoodRx. (n.d.).
  8. Stewart E. Lawmakers seem confused about what Facebook does—and how to fix it. Vox. 2018 Apr 10.
  9. PBM Resources. National Community Pharmacists Association. (n.d.).
  10. Thomas K. Meet the rebate, the new villain of high drug prices. The New York Times. 2018 Jul 27.
  11. Hiltzik M. The ‘clawback’: Another hidden scam driving up your prescription prices. Los Angeles Times. 2017 Aug 9.
  12. Managed care Medicaid’s top 20 over $20 list. 46Brooklyn. 2019 Aug 20.
  13. PMCS and EBRx announce the first fully-transparent benefit administrator. BusinesWire. 2004 Aug 27.
  14. MBGH calls on employers to rethink pharmacy benefit strategies. PR Newswire. 2017 Sep 13.
  15. Kelley T. When the cost of medications keep patients from taking them. Managed Care. 2018 Jun 3.
  16. Herman B. States are the new battleground for drug price middlemen. Axios. 2018 Dec 19.
  17. Pierce CP. Elizabeth Warren should include her ‘markets without rules are theft’ line in every speech. Esquire. 2019 Mar 19.
  18. Gelles D, Yaffe-Bellany D. Shareholder value is no longer everything, top C.E.O.s say. The New York Times. 2019 Aug 19.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:GoodRxpharmacy benefit administratorspharmacy benefit managers (PBMs)

Related Articles

    Mark Cuban: Mixing Up the Pharmaceutical Landscape

    April 7, 2023

    The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…

    Generic-Drug Price Fixing: Is It Happening?

    May 17, 2018

    It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

    Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

    June 14, 2017

    While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

    The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

    June 15, 2017

    Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences